Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2022

View Archived Issues

ADAM10 may be a promising therapeutic target for AML

Sunshine Lake Pharma patents new GCGR and/or GLP-1 receptor agonists

Eubulus Biotherapeutics discloses new GPX4 inhibitors

Roche presents new EGFR mutant inhibitors

Reistone Biopharma divulges new CatC inhibitors

Palacky University patents new terpenoid derivatives

Novel mouse models of BrafV600E-driven thyroid tumors

Alaunos and NCI extend CRADA to assess use of Sleeping Beauty technology for TCR T-cell therapy

Ascentage receives IND clearance for first-in-human study of EED inhibitor APG-5918

HNSCC treatment should focus on targeting TSPAN1

Generian and Mitobridge collaborate to discover and develop small molecules for undruggable targets

Tumors might be nudged to more treatable state

IAMA reports responses with selective NKCC1 inhibitors in animal models of Down syndrome and autism

Anti-VISTA monoclonal antibody KVA-12.1 produces antitumor responses in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...